BiomX Inc. (PHGE)

NYSE Biotechnology Diagnostics SIC: 2836
D
Pipeline Grade

Financial Position (from SEC Filings)

$1.2M
Cash & Equivalents
$5.4M
Quarterly Burn Rate
1 mo
Est. Cash Runway
$3M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT06998043 Study With Phage for CF Subjects With Pseudomonas Lung Infection PHASE2 Recruiting 63

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for PHGE.

SEC EDGAR Filings

All SEC filings for BiomX Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.